Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | LGMN | Q99538 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837455 | 0.88 | SHMT2 (0.59) | SHMT2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL3837306 | 0.84 | LMNA (0.53) | SHMT2KDM4ETSHRHTTGAA | |
| SCHEMBL31557346 | 0.82 | MAPT (0.58) | SHMT2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL3840918 | 0.80 | P2RX7 (0.52) | SHMT2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL3838814 | 0.79 | P2RX7 (0.62) | SHMT2 | |
| SCHEMBL5122223 | 0.78 | P2RX7 (0.49) | SHMT2MAPTKMT2AMEN1BLM | |
| SCHEMBL5121876 | 0.78 | MAPT (0.51) | SHMT2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL5128913 | 0.78 | P2RX7 (0.49) | SHMT2MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3837434 | 0.78 | P2RX7 (0.52) | SHMT2MAPT | |
| SCHEMBL5125855 | 0.78 | P2RX7 (0.48) | SHMT2MAPTALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | SHMT2 1950/4885MAPT 1761/4885ALDH1A1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.